Prospective validation for the usefulness of Genome-wide association study (GWAS) in predicting the effects of anti-viral therapy on chronic hepatitis C - Chronic hepatitis C and GWAS

Research Center for Hepatitis & Immunology, Kohnodai Hospital, International Medical Center of Japan0 个研究点目标入组 250 人开始时间: 2009年10月8日最近更新: 2023年10月17日

试验速览

暂无简介。

•1) Patients taking Sho-sai-koto(herbal medicine) 2) Autoimmune hepatitis 3) Patients with history of interstitial pneumonia 4) Patients with previous history of drug allergy against ribavirin, peginterferon alpha2a (Pegasys), peginterferon alpha2b (Pegintron), or other interferons 5) Patients with previous history of drug allergy against biological products such as vaccines 6) Liver cirrhosis, liver failure or hepatocellular carcinoma 7) Patients with the following laboratory data at the start of peginterferon and ribavirin combination therapy: WBC counts less than 4,000/microliter and Neutrophil counts less than 1,500/microliter; Platelets counts less than 90,000/microliter (peginterferon alpha2a) or 100,000/microliter(peginterferon alpha2b); Hemoglobin levelsless than 12g/dL 8) Women who are pregnant or have its possibility 9) Patients who refuse birth control, including male patients whose patners may have the chance to be pregnant 10) Patients whom the physicians in charge judge their enrollment inappropriate

发起方

Research Center for Hepatitis & Immunology, Kohnodai Hospital, International Medical Center of Japan